# A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Source: https://onco.cc/trials/nct07678593/  
OnCo record `nct07678593` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of cetuximab, nab-paclitaxel, gemcitabine, fluorouracil (5-FU) and other drugs in pancreatic cancer, run by Genfleet Therapeutics (Shanghai) Inc., not yet recruiting.

## Summary

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation is a phase 1/2, interventional study registered as NCT07678593 by Genfleet Therapeutics (Shanghai) Inc., with a registry enrolment figure of 222 participants, started 2026-09 and due to reach its primary completion in 2027-11. Interventions recorded: GFH276; Cetuximab; Nab paclitaxel; Gemcitabine; Fluorouracil; Leucovorin; Irinotecan; Oxaliplatin. Conditions listed: Advanced Solid Tumors Cancer; Pancreatic Ductal Adenocarcinoma; RAS Mutation. Primary outcome: Phase Ib:Incidence of Dose-Limiting Toxicity (DLT) Events; Phase Ib:Incidence and Severity of Adverse Events (AE) and Serious Adverse Events (SAE); Phase II:Objective Response Rate (ORR). Sites: Australia, China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07678593
- Phase: 1/2
- Setting: A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
- Sponsor: Genfleet Therapeutics (Shanghai) Inc.
- Enrolled: 222

## Sources

- ClinicalTrials.gov NCT07678593: https://clinicaltrials.gov/study/NCT07678593

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07678593.json